June 5

BASINGSTOKE, England, June 5, 2011 - - Pivotal Phase III ALIMTA study met primary endpoint Eli Lilly and Company Limited announced today that PARAMOUNT(1), Lilly Oncology's Phase III study evaluating ALIMTA(R) (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is alive without their disease worsening, for patients with a specific type of lung cancer called advanced nonsquamous non-small cell lung cancer (NSCLC).

WATERLOO, Ontario, June 5, 2011 - - Cover Unique Global Energy Summit On-line In 2030, when you plug in your toaster, car or smart phone, where will the electricity come from? Or, will the electrons be there at all? In the midst of Japan's Fukushima nuclear disaster and as summer peak electricity demand looms in the northern hemisphere, world-leading energy scientists, future leaders and a group of experienced advisors are meeting in a unique think-tank experiment to envision how we can best prepare for a sustainable and safe global electricity future.

KIGALI, Rwanda, June 5, 2010 - High-ranking UN VIPs, well-known environmental advocates, a glamorous party and above all: the best environmental projects in the world - that was the ENERGY GLOBE Gala - Rwanda 2010.

FRIMLEY, England, June 5, 2010 - - Data show zoledronic acid, a bisphosphonate, provided significant clinical anticancer benefit and significantly reduced risk of skeletal- related events(1,2) - Overall survival advantage observed with zoledronic acid plus chemotherapy versus oral clodronate plus chemotherapy is independent of skeletal-related event benefit(1) - Results from a separate five-year follow-up study of hormone receptor-positive premenopausal early breast cancer patients showed significant improvement in progression-free survival with zoledronic acid in this patient population(2) New data to be presented tomorrow at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, from the Myeloma IX study, show that zoledronic acid plus first-line chemotherapy significantly improved overall survival for newly diagnosed multiple myeloma patients by 16% (P=0.0118) and progression-free survival by 12%, (P=0.0179) compared to oral clodronate plus first-line chemotherapy(1).

PARIS, June 7, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS).